anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
Heavy eye syndrome (HES) is an atypical form of strabismus, primarily caused by a significant elongation of the axial length of the eye, which leads to a disruption of normal topographic relationships between the posterior pole and the extraocular muscles. Clinical symptoms of HES include late-onset convergent strabismus (esotropia) with a vertical component and restricted ocular motility in the context of substantial eye enlargement associated with high myopia. Identification of the pathognomonic sign (dislocation of the posterior pole from the muscle cone) requires the use of multislice computed tomography (MSCT) of the orbits. Considering the mechanism of HES development, the surgical treatment of choice is various techniques for approximating the superior and lateral rectus muscles, which can be regarded as pathogenetically oriented treatment. If necessary, these procedures may be supplemented by classical interventions. The use of classical surgical techniques (recession and resection) as standalone first-stage treatments for HES is inadvisable, not only due to their insufficient efficacy but also because they may complicate subsequent pathogenetically oriented interventions.
Objective Molecular-targeted agents, including eculizumab and rituximab, are considered treatment options for refractory myasthenia gravis (MG), but bacterial infections can occur as serious adverse events when using these agents. The present study elucidated the relative risks of bacterial infections associated with eculizumab and rituximab using a pharmacovigilance database. Methods We analyzed eculizumab- and rituximab-associated adverse events reported between 2007 and 2021 in the US Food and Drug Administration Adverse Event Reporting System (FAERS) and herein report a refractory MG patient who developed streptococcal toxic shock syndrome during eculizumab treatment. Patients We evaluated a 74-year-old Japanese woman with refractory MG who developed severe bacteremia after receiving eculizumab. Results A total of 44,215 and 108,485 adverse events were reported with eculizumab and rituximab, respectively, from among 13,742,321 individual case safety reports in the FAERS database after data cleaning. We found a strong association between eculizumab and Neisseria infections. In contrast, we found only one case of meningococcal meningitis treated with rituximab. Both eculizumab and rituximab were weakly associated with streptococcal infections. Two cases of streptococcal toxic shock syndrome were associated with rituximab. Conclusion Careful monitoring of serious bacterial infections associated with eculizumab treatment is warranted.
The invention provides a porous hemostatic powder which is prepared by carrying out physical drilling on a soluble material to form porous microspheres. A preparation method of the porous styptic powder comprises the following steps: putting the soluble material on a supersonic vibration bed device, starting the device, vibrating, and simultaneously carrying out laser radiation for 10-60 min. The soluble material undergoes laser drilling. The preparation method has advantages of simple technology, easy operation, low production cost and wide raw material sources. Soluble starch, carboxy methyl starch, hydroxyethyl starch, carboxymethylcellulose sodium, ethyl cellulose or sodium alginate and their derivatives are medically proved to be safe medical materials, are generally used as pharmaceutic adjuvants and sustained release agents of medicines, and are also used to prepare absorbable hemostatic gauze such as Tailing absorbable hemostatic gauze. These materials are all dissoluble; the size of molecular weight is controllable; preferably, the molecular weight is 500-12000Dalton; more preferably, the molecular weight is 1000-40000 Dalton; and the materials all can be absorbed by body.
PROBLEM TO BE SOLVED: To obtain the laminate capable of stably releasing a medicine over a long period by forming holes having a specific size in the outside film of a laminate comprising a film and a medicine-impregnated layer to arbitrarily control the release rate of the medicine. SOLUTION: This laminate comprises a thermoplastic resin film and a medicine-impregnated porous layer. Holes wherein the value of A expressed by the equation is >=2.5 are formed in one or both outside films of the laminate. The holes are preferably formed by heating the thermoplastic resin film. The film is preferably the one consisting mainly of a polyethylene terephthalate and having a crystal-melting heat of <=45J/g. The porous layer is preferably a non-woven fabric comprising synthetic fibers. The laminate is preferably obtained by thermally adhering the film to the non-woven fabric and subsequently biaxially orienting the produced laminate. The medicine sustained release laminate has preferably an adhesive material layer having adhesivity to skin.
BACKGROUND AND OBJECTIVE: Post-coronavirus disease (COVID) persistence of symptoms and the development of complications have become frequently encountered clinical problems due to multiple waves of the pandemic over the past 3 years across the world. Identifying risk factors would enable us to direct our limited resources toward the subgroups requiring long-term follow-up and treatment. With this prospective observational study, we aim to establish a statistical correlation between the persistence of symptoms and four of the most attributed risk factors for prolonged recovery: severity of acute illness, elderly age, presence of multiple comorbidities, and female gender in the Indian population.
MATERIALS AND METHODS: Three hundred patients with positive COVID reverse transcription polymerase chain reaction (RTPCR) or antigen tests were enrolled over 10 months (from December 2020, after obtaining ethical clearance, to October 2021). Symptoms were recorded at baseline and followed up with a predesigned questionnaire to assess their persistence at 1-, 2-, and 4-month intervals post-COVID recovery. Appropriate statistical analysis [Pearson's correlation/analysis of variance (ANOVA) test] was used to establish the correlation between the persistence of symptoms and their severity with the presence of risk factors.
RESULTS: Severity of acute illness was the single most important determining factor of persistence of symptoms as well as their severity in our study (p < 0.001) at each follow-up interval. The correlation observed between average number or severity of persistent symptoms increased with female gender, increasing age-group and presence of multiple comorbidities was not significant statistically (p > 0.05) with exception of persistent fatigue in females at 2-month interval.
INTERPRETATION AND CONCLUSION: Persistent symptoms and its prevalence recorded so far represents tip of the iceberg of patients suffering with long COVID. Patients with history of severe acute illness should be followed up closely for prompt identification and rehabilitation of these cases as it had maximum bearing on the outcome of these patients.
Screening for C. trachomatis and N. gonorrhoeae STIs at 3 anatomical sites, i.e. pharyngeal, urogenital and anal, is recommended every three to six months in MSM with high-risk sexual behaviors, using NAAT. A positive NAAT result defines the patient as infected, and the patient will receive antibiotic treatment. However, repeated use of antibiotics has led to the emergence of multi-drug resistant strains of M. genitalium, another STI agent, and N. gonorrhoeae, and to changes in the gut microbiota. One disadvantage of NAATs is that they amplify the nucleic acids of viable and dead bacteria. Thus, it is not possible to affirm that the patient has an "active" infection, defined by the presence of viable bacteria. Bacterial viability can be studied by real-time PCR (called V-PCR). This method combines the high sensitivity and specificity of PCR with the ability to exclude detection of nucleic acid remnants from non-viable bacteria. It does so by incorporating a sample pretreatment step with a membrane impermeable DNA intercalating dye prior to molecular analysis by blocking amplification of remnant DNA from non-viable bacteria. This allows the V-PCR analysis to detect DNA originating from intact (i.e. viable) bacteria. Using V-PCR, studies in women have shown that only half of the anorectal samples and one quarter of the pharyngeal samples positive for C. trachomatis contain viable bacteria.

The team proposes to investigate the presence of viable C. trachomatis, N. gonorrhoeae and M. genitalium bacteria by V-PCR in pharyngeal, urogenital and anal specimens from MSM detected as positive by NAAT for these bacteria.

The results of this work will allow us to assess whether all types of specimens tested in these patients contain viable bacteria, and if so, in what proportions.
We previously found IQ motif containing GTPase activating protein (IQGAP1) to be consistently elevated in lung fibroblasts (LF) isolated from patients with scleroderma (systemic sclerosis, SSc)-associated interstitial lung disease (ILD) and reported that IQGAP1 contributed to SSc by regulating expression and organization of α-smooth muscle actin (SMA) in LF. The aim of this study was to compare the development of ILD in the presence and absence of IQGAP1. Pulmonary fibrosis was induced in IQGAP1 knockout (KO) and wild-type (WT) mice by a single-intratracheal instillation of bleomycin. Two and three weeks later, mice were euthanized and investigated. We observed that the IQGAP1 KO mouse was characterized by a reduced rate of actin polymerization with reduced accumulation of actin in the lung compared to the WT mouse. After exposure to bleomycin, the IQGAP1 KO mouse demonstrated decreased contractile activity of LF, reduced expression of SMA, TGFβ, and collagen, and lowered overall fibrosis scores compared to the WT mouse. The numbers of inflammatory cells and expression of pro-inflammatory cytokines in lung tissue were not significantly different between IQGAP1 KO and WT mice. We conclude that IQGAP1 plays an important role in the development of lung fibrosis induced by bleomycin, and the absence of IQGAP1 reduces the contractile activity of lung fibroblast and bleomycin-induced pulmonary fibrosis. Thus, IQGAP1 may be a potential target for novel anti-fibrotic therapies for lung fibrosis.
Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg four times daily for the first 2 to 4 days, increase to 25 mg four times daily for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg four times daily. For maintenance, adjust dosage to the lowest effective levels.

The incidence of toxic reactions, particularly the L.E. cell syndrome, is high in the group of patients receiving large doses of hydrALAZINE hydrochloride tablets.

In a few resistant patients, up to 300 mg of hydrALAZINE hydrochloride tablets daily may be required for a significant antihypertensive effect. In such cases, a lower dosage of hydrALAZINE combined with a thiazide and/or reserpine or a beta blocker may be considered. However, when combining therapy, individual titration is essential to ensure the lowest possible therapeutic dose of each drug.
FIELD: cosmetology. SUBSTANCE: coloring composition for keratin fibers, particularly, man's hair, contains a direct cationic coloring in medium for coloring. The composition additionally includes a cationic or amphoteric substantive polymer. The invention deals with methods of coloring and packaging of kit for coloring and using of said composition. EFFECT: lower-selective coloring more stable to aggressive influence. 24 cl
NEW MATERIAL:The compound of formula (the 105-Cys is bonded with the 121- Cys through disulfide bond). USE:Diuretic and hypotensor. PREPARATION:The atrium of rat is homogenized in 1N acetic acid and extracted with acetone, etc. The extract liquid is centrifuged, and the supernatant liquid is distilled in vacuum to remove acetone, added with 1:2 mixture of acetic acid and water, subjected to the reverse-phase column chromatography, and eluted with 40:60:1 mixture of water, acetonitrile and 10% trifluoroacetic acid. The eluted fraction is freeze-dried, dissolved in 1N acetic acid, and subjected to gel-filtration to obtain a fraction active to relax the specimen of chicken ileum. The objective peptide called as gamma-rANP (gamma-rat atrial natriuretic polypeptide) can be prepared by the high-performance liquid chromatography of the above fraction.
PURPOSE:To provide the titled liquid containing a variety of amino acids necessary for the biosynthesis of proteins and capable of promoting the synthesis of tissue proteins, by preparing a fermentation liquid from rice malt, cereal, and water, separating acetic acid from the liquid, and using the resultant concentrated fermentation liquid as an active component. CONSTITUTION:A fermentation liquid is prepared from rice malt, cereal and water Acetic acid is separated from the liquid, and the obtained concentrated fermentation liquid is used as an active component of the titled liquid agent. Especially a liquid having a concentration of 2% exhibits the action to promote the smooth healing of the wound during the whole period from the early stage of the wound to the healing stage. The concentrated fermentation liquid contains 20 kinds of l-amino acids (e.g. aspartic acid, glycine, glutamic acid, etc.) including the essential amino acids constituting the cell proteins of the human body in balanced amounts. The amino acids act at the same time on the wound to replenish the tissue proteins lost by acute inflammation smoothly and to promote healing of the wound at an early stage.
The seven sessions will cover: 1) nutrition (2 sessions), 2) sleep hygiene, 3) building immunity (e.g., how to avoid colds/flu), 4) injury/disease prevention (e.g., seat belts, sunscreen, when to get regular check-ups/screenings etc.), 5) benefits of exercise/cardiac health, 6) alternative medicine (massage, acupuncture). These sessions will be primarily didactic and consist of health education, followed by discussion as to how this information compares to that which the participants may have been exposed to in the past.
A pharmaceutical preparation for oral administration in unit dosage form, effective in the treatment of diseases caused by the protozoa family Trypanosomidae comprises 6-methoxy-8 - (6 - piperazino hexyl amino) - quinoline, or an acid addition salt thereof in admixture with a carrier therefor.  Specified acid addition salts are the trihydrochloride oxalate and the dimaleate. The preparation may be a tablet, a capsule e.g. gelatin capsule or p  a cachet.  The tablets may be enteric coated by applying cellulose acetate phthalate dissolved in a mixture of ethyl acetate, ethanol and ethyl lactate. Specified carriers are lactose, starch and magnesium stearate. Specification 921,315 is referred to.
Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using \<1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
An improved method of administration of microspheres of cytotoxic chemicals to tumor sites without effect on non tumor tissue is disclosed. The method comprises injection of chemotherapeutic agents coated with a thermoplastic polymer having a melting point above normal body temperature (in a melting point range of about 40°-46° C.) accompanied by dielectric radio-frequency localized heating of the tumor to elevate its interior temperature above the melting point of the encapsulating thermoplastic polymer. The tumor is partially necrosed and sensitized by the R.F. nonionizing radiation bombardment and the entry of the chemotherapy agent triggered by the removal of the protective coat of thermoplastic polymer. 
     A preferred embodiment of the invention is a dose of 30 mg of methotrexate (A-methopterin) in the form of spherical microscapsules having an average of 200-800 microns diameter and a polymer of polystearyl acrylate encapsulating coating of an average thickness of 1-50 microns. This dose is injected into the tumor and released by a 30-60 minute irradiation of the tumor by 175-200 watts of R.F. non-ionizing radiation at a frequency of 13.56 megahertz from a set of capacitive plates positioned on opposite sides of the impregnated tumors. The tumor temperature is elevated to a threshold temperature of 43° C. which is the melting point and release point of the encapsulated acrylic resin. The temperature of the rest of the organism outside the tumor remains at 39°-40° C. which is below the release temperature of the resin.
A randomized study to evaluated the safety and effect of nasal carbon dioxide on nasal congestion using acoustic rhinometry in subjects with perennial allergic rhinitis. The acoustic rhinometry is an instrument that will be used to assess the levels of the nasal congestion in each subject. Approximately 20 men and women ages 19-65 years old who have a history consistent with perennial allergic rhinitis requiring pharmacology for at least 2 years and meet all other eligibility criteria will be enrolled in this study. There will be six (6) visits to the clinic. There will be a screening visit, four (4) treatment visits, and an end of study visit. A subject's participation in the study may last up to 58 days. There will be four different doses given in this study. Each subject will receive 3 different doses of the study drug and one dose of the placebo.
This is a monocenter, open-label, non-placebo-controlled, single-group, single-dose study. Six male subjects will receive a single dose of Pyronaridine 720 mg orally administered together with 14C-Pyronaridine (approx. 100 µg, 800 nCi (29600 Bq)).

Safety measurements (12-lead ECG, vital signs, blood chemistry and haematology) and adverse events will be monitored throughout the study. Subjects will come to the clinic the evening before the dosing of Pyronaridine. After the drug intake at day 1, subjects will have regular in-house periods for specimen collection up to 87 days after the drug administration. Blood, feces and urine will be collected during the hospitalisation periods. Samples will be analyzed for radioactivity by Accelerator Mass Spectrometry (AMS).
The invention relates to medicine, and specifically to orthopaedics and orthodontia, and can be used for planning bite correction. A general and dental history is taken. Mental status is determined. The patient's musculoskeletal system is analysed. A polysomnography examination is performed. Body weight and size is measured. Functional diagnostics is performed. All of the resulting data are transferred to a computing unit. When deviations from the norm of values for the respiratory organs and the musculoskeletal system are detected in conjunction with bite problems, pathologies are diagnosed that disrupt organ function in the body systems investigated in a waking state and/or during sleep and associated with bite. A plan of action to correct the identified pathologies is defined, along with bite correction. The method makes it possible to decrease functional problems in the body by virtue of the complex approach to human diagnosis and treatment.
Chronic endometritis is associated with the imbalance of female reproductive tract microbiota and pathogenic microbial infection. This study aimed to identify the specific changes in the endometrial microbiome in patients with endometritis and to explore how Clostridium tyrobutyricum (C.t) influences the progression of endometritis in mice for further elucidating endometritis pathogenesis. For this purpose, endometrial tissues from 100 participants were collected and divided into positive, weakly positive, and negative groups based on CD138 levels, while endometrial microbiome differences were detected and analyzed using 16S rRNA gene sequencing. Staphylococcus aureus (S. aureus)-induced endometritis mouse model was established, followed by treatment with C.t, and inflammatory response, epithelial barrier, and TLR4/NF-κB pathway were evaluated. Results showed that α- and β-diversity was significantly lower in the positive group compared with the weakly positive or negative groups, where the negative group had more unique operational taxonomic units. The abundance of Proteobacteria was found to be increased, while that of Actinobacteria, Firmicutes, and Bacteroidetes was found to be reduced in the positive group, while the area under the curve value was found to be 0.664. Furthermore, C.t treatment resulted in the alleviation of S. aureus-induced inflammatory response, epithelial barrier damage, and activation of the TLR4/NF-κB pathway in mice. Clinical samples analysis revealed that the diversity and abundance of microbiota were altered in patients with endometritis having positive CD138 levels, while mechanistic investigations revealed C.t alleviated S. aureus-induced endometritis by inactivating TLR4/NF-κB pathway. The findings of this study are envisaged to provide a diagnostic and therapeutic potential of microbiota in endometritis.
The invention relates to an eosinophilic kidney type avian infectious bronchitis virus (IBV) vaccine strain, in particular to an eosinophilic kidney type IBV virulent vaccine strain and application thereof, belonging to the technical field of organisms. The eosinophilic kidney type avian IBV virulent vaccine strain has CGMCC (China General Microbiological Culture Collection) No. 3957, and fiber axon protein of the eosinophilic kidney type avian IBV virulent vaccine strain has a gene sequence shown as SEQ ID NO:1. The invention provides a vaccine composition which comprises the eosinophilic kidney type avian IBV virulent vaccine strain and pharmaceutically acceptable adjuvants or carriers. The eosinophilic kidney type IBV virulent vaccine strain provided by the invention has favorable immunogenicity to the current epidemic eosinophilic kidney type IBV. A vaccine prepared by a DS10 virus not only can effectively resist the attack of self virulent strains, but also can effectively prevent the attack of a respiratory vaccine strain, therefore, the avian IBV can be effectively prevented and treated.